Journal News

JLR: A close-up of nascent HDL formation

Laurel Oldach
Jan. 1, 2019

Oil and water don’t mix. But our aqueous blood is full of hydrophobic lipids — including cholesterol. To travel via the bloodstream, those lipids must hitch a ride on an amphipathic carrier. In a paper in the Journal of Lipid Research, scientists at Boston University report an advance in our mechanistic understanding of how one such carrier forms.

“Lipoproteins are like boats that deliver and remove cargoes of fatty substances to and from our cells,” said David Atkinson, chair of the physiology and biophysics department at Boston University School of Medicine and senior author on the JLR paper.

The subset of those “boats” that carry cholesterol and other lipids to the liver from other parts of the body are called high-density lipoproteins, or HDL, aka “good cholesterol.” HDL can remove cholesterol from distal cells — such as macrophages in the walls of arteries, where cholesterol accumulation can lead to heart attacks — and deliver it to liver cells, a process known as reverse cholesterol transport. The liver disposes of excess cholesterol by converting it into bile acids secreted into the small intestine.

According to Atkinson, a biophysicist, most of what is known about HDL formation comes from experiments that take a cell biological tack. In such studies, he said, “You can see (HDL formation) happening, and you can quantitate what happens, but you don’t understand the driving interactions that cause it to happen.”

HDL is built on a scaffold protein, apolipoprotein A-I. This apoA-I is thought to collect cholesterol and phospholipids from the cell membrane. Atkinson’s team wanted to better understand that process.

Lipoprotein particleA model of a high-density lipoprotein particle shows apolipoprotein A-I in pink, phospholipids in gray and cholesterol in yellow.Wu et al/JBC 2009ApoA-I depends on a lipid transporter protein, ABCA1, that pumps cholesterol from the inner to the outer leaflet of the cell membrane. Because the cholesterol that ABCA1 transfers usually ends up bound to apoA-I, some researchers suspected a physical interaction between apoA-I and ABCA1. Others argued that cholesterol and phospholipids could diffuse passively and bind to apoA-I.

“Even if you demonstrate that apoA-I binds to the cell surface, you don’t actually know that it’s bound to ABCA1. It’s just bound to the cell surface,” Atkinson said. So he asked his team to see if they could “demonstrate that interaction actually happening in the isolated components.”

The team, led by graduate student Minjing Liu and supported by Xiaohu Mei and Haya Herscovitz, used isolated apoA-I and ABCA1 to test for a physical interaction. They were able to show immunoprecipitation of apoA-I with purified ABCA1.

The lab earlier had designed a mutant apoA-I with a little extra wiggle in an already flexible hinge region. For this study, they used the mutant to show that higher flexibility increased apoA-I lipidation, or the formation of nascent HDL. The team has not yet tested whether the extra-flexible mutant binds to ABCA1 better or whether binding of either form of apoA-I activates ABCA1.

But about one thing Atkinson is certain: “It’s the apoA-I/ABCA1 interaction which then enables the nascent HDL particle formation to happen as the membrane components are being transported out by ABCA1.”

Increasing reverse cholesterol transport may be a way to reduce atherosclerosis and heart disease. Atkinson is optimistic about the promise of understanding the physiological processes better.

“Translational research might be in vogue,” he said, “but remember that if you don’t do foundational basic discovery research, you will not have anything to translate.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Laurel Oldach

Laurel Oldach is a former science writer for the ASBMB.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

‘Inert’ ingredients in pesticides may be more toxic to bees than scientists thought
News

‘Inert’ ingredients in pesticides may be more toxic to bees than scientists thought

Dec. 9, 2023

Pesticide users sometimes know very little about how inerts function. That’s partly because they are regulated very differently than active ingredients.

FDA approves CRISPR–Cas9 therapy for sickle cell disease
News

FDA approves CRISPR–Cas9 therapy for sickle cell disease

Dec. 8, 2023

The gene editing treatment from Vertex Pharmaceuticals and CRISPR Therapeutics is the first of its kind

From the journals: MCP
Journal News

From the journals: MCP

Dec. 8, 2023

Metals contaminate protein samples. Lipid droplets go haywire in Huntington’s. Nerve cells respond to stimulation. Read about these recent papers.

The perfect storm
Feature

The perfect storm

Dec. 6, 2023

The world has 2023 Nobel laureates Katalin Karikó, Drew Weissman and others to thank for laying a foundation for the COVID-19 vaccine decades before the pandemic.

Throw your hat in the ring!
Annual Meeting

Throw your hat in the ring!

Dec. 6, 2023

Apply to speak at Discover BMB in Chicago in 2025.

How bacteria inhibit gene expression
Journal News

How bacteria inhibit gene expression

Dec. 5, 2023

Researchers show how altering activity of the transcription factor CarD can cause downregulation and upregulation of some genes.